Received Feb 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
I'm having more trouble breathing since the shot; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of difficulty breathing in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced difficulty breathing (Verbatim: trouble breathing). The outcome of the difficulty breathing was not reported. It was unknown if the reporter considered the difficulty breathing to be related to Arexvy. It was unknown if the company considered the difficulty breathing to be related to Arexvy. Additional Information: GSK Receipt Date: 19-JAN-2025 This case was reported by a patient via interactive digital media. The reporter reported that he/she had more trouble breathing since the shot.